List of Excipients in Branded Drug ENTECAVIR

« Back to Dashboard

Generic Drugs Containing ENTECAVIR

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	entecavir	0093-5786	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	entecavir	0093-5786	CROSPOVIDONE
Teva Pharmaceuticals USA Inc	entecavir	0093-5786	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	entecavir	0093-5786	MANNITOL
Teva Pharmaceuticals USA Inc	entecavir	0093-5786	POLYETHYLENE GLYCOL 3350

What are the Most Frequently-Used Excipients in ENTECAVIR?

# Of NDCs	Excipient
2	CALCIUM CARBONATE
2	CARBOXYMETHYLCELLULOSE SODIUM
25	CELLULOSE, MICROCRYSTALLINE
2	CITRIC ACID MONOHYDRATE
22	CROSPOVIDONE

Entecavir Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 24, 2026

Entecavir is a low-dose oral nucleoside analogue for chronic hepatitis B virus infection. The commercial opportunity is concentrated in generic tablets, pediatric and dysphagia-friendly liquids, orally disintegrating formats, taste-masked dosage forms, and differentiated global products. Because entecavir is administered at only 0.5 mg or 1 mg, content uniformity, blend segregation, dissolution, and dose-measurement accuracy are more important than raw drug-load economics.

The original Baraclude product contains conventional excipients rather than a proprietary delivery platform. Its formulation profile leaves room for lower-cost generic development, improved pediatric acceptability, preservative-free liquids, orally disintegrating tablets, and stability-focused presentations. Entecavir is a small molecule, so biosimilar regulation does not apply.

What is entecavir and how is it formulated?

Entecavir is a guanosine nucleoside analogue that inhibits hepatitis B virus polymerase. Bristol-Myers Squibb commercialized it as Baraclude in 0.5 mg and 1 mg tablets and as a 0.05 mg/mL oral solution. The U.S. Food and Drug Administration approved Baraclude in March 2005 for adults with chronic hepatitis B and later expanded its labeling to include pediatric patients at least 2 years of age with adequate body weight and renal function considerations (FDA, 2023a).

Reference product dosage forms

Product	Strength	Route	Primary commercial use
Baraclude tablet	0.5 mg	Oral	Treatment-naive adults and selected pediatric patients
Baraclude tablet	1 mg	Oral	Lamivudine-refractory or resistant patients and selected adults
Baraclude oral solution	0.05 mg/mL	Oral	Patients unable to swallow tablets, including pediatric patients

The tablets use a conventional immediate-release architecture. The listed core excipients include lactose monohydrate, microcrystalline cellulose, crospovidone, povidone, and stearic acid. The film coating uses standard coating materials, including hypromellose and titanium dioxide. The oral solution uses maltitol, citrate buffers, preservatives, sucralose, flavoring, and purified water, according to U.S. labeling (FDA, 2023a; DailyMed, 2024).

What excipient strategy is most suitable for entecavir tablets?

A direct-compression or dry-granulation platform is generally the most commercially efficient strategy for generic entecavir tablets. The low dose makes blend uniformity and segregation control the principal formulation risks.

Recommended tablet excipient architecture

Formulation function	Suitable excipient classes	Commercial rationale
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol	Provides tablet mass and supports content uniformity
Binder	Povidone, copovidone, low-substituted hydroxypropyl cellulose	Improves compactability at low drug loading
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid immediate-release dissolution
Glidant	Colloidal silicon dioxide	Reduces flow variability and hopper segregation
Lubricant	Magnesium stearate, sodium stearyl fumarate, stearic acid	Controls ejection force and tooling adhesion
Film coat	Hypromellose, polyvinyl alcohol, titanium dioxide, iron oxides	Protects the tablet and supports identification
Taste control	Film coating, ion-exchange resin, polymeric barrier	Relevant for pediatric or chewable presentations

A lactose-microcrystalline cellulose blend is a logical starting point because it combines flow, compactability, and established regulatory precedent. Mannitol is more attractive where mouthfeel, cooling sensation, or sugar-free positioning is important. Sodium stearyl fumarate may be evaluated when magnesium stearate causes dissolution sensitivity or hydrophobic over-lubrication.

Why low-dose content uniformity matters

Entecavir tablets contain 0.5 mg or 1 mg of active ingredient. The active drug can represent well below 1% of total tablet weight. That creates four principal risks:

1. Inadequate preblend uniformity.
2. Segregation during transfer and compression.
3. Over-lubrication and delayed dissolution.
4. Assay variability caused by sampling error.

A robust development program should control particle-size distribution, morphology, bulk density, electrostatic behavior, and the order of excipient addition. Geometric dilution, ordered blending, low-shear transfer, and validated in-process sampling are more valuable than adding a large number of novel excipients.

For an immediate-release generic, excipient novelty may increase regulatory risk without creating a meaningful commercial advantage. A conventional platform with strong process capability is usually preferable to a complex formulation that provides no clear patient benefit.

What formulation opportunities exist for pediatric entecavir?

Pediatric formulation is the strongest excipient-led opportunity. The approved oral solution demonstrates that liquid administration is clinically relevant, but a generic developer can compete through improved taste, packaging, dosing accuracy, preservative strategy, and global supply economics.

Oral solution opportunities

The reference oral solution uses maltitol as a bulk sweetener and sucralose as an intense sweetener. Citric acid and sodium citrate provide buffering, while methylparaben and propylparaben support antimicrobial preservation (FDA, 2023a).

Potential differentiation areas include:

• Improved flavor systems that reduce bitterness and lingering aftertaste.
• Sugar-free and alcohol-free presentations.
• Lower preservative load or preservative-free unit-dose packaging.
• Improved compatibility with oral syringes and enteral administration.
• Reduced viscosity to improve dose withdrawal.
• Unit-dose sachets or premeasured oral syringes.
• Improved stability after opening.
• Child-resistant packaging with senior-friendly dosing access.

The main technical challenge is balancing palatability, preservative efficacy, pH, chemical stability, and microbial control. A sweetener system can alter viscosity and osmolality. Flavor components can interact with container-closure materials or complicate analytical methods.

Orally disintegrating and mini-tablet formats

An orally disintegrating tablet could address children and adults with swallowing difficulty. Mannitol, crospovidone, co-processed excipients, and taste-masking polymers are plausible tools. The low entecavir dose is favorable for mini-tablets, but bitterness and dose uniformity remain key obstacles.

A pediatric mini-tablet or dispersible tablet may have a stronger commercial position than a conventional tablet if it reduces caregiver dosing errors and eliminates the need for a multidose liquid bottle. It would require a product-specific bioequivalence and pharmaceutical equivalence strategy under the applicable regulatory pathway.

What patents protect entecavir and its formulations?

The foundational U.S. entecavir compound patent was U.S. Patent No. 5,206,244, assigned to Bristol-Myers Squibb-related entities. The patent covered carbocyclic nucleoside analogues, including entecavir, and expired in the United States after the original term and applicable pediatric extension. The core compound protection is therefore no longer the principal barrier to U.S. generic entry.

Historical U.S. exclusivity profile

Asset	Type	Commercial relevance
U.S. Patent No. 5,206,244	Foundational compound patent	Protected entecavir and related carbocyclic nucleosides
Baraclude NDA 021797	FDA approval	Established the reference product
Pediatric exclusivity	Regulatory extension	Delayed certain generic approvals after the original patent term
Product-specific formulation or use claims	Potential secondary protection	Must be assessed by jurisdiction and Orange Book status

The commercial value of secondary patents depends on whether they claim a clinically meaningful formulation, a specific method of treating HBV, a manufacturing process, or a narrow solid-state form. Excipient choices alone generally do not create strong exclusionary rights unless they are tied to a specific composition, performance result, or manufacturing process.

What is the Orange Book status of entecavir?

The FDA Orange Book identifies approved drug products, applicants, therapeutic-equivalence codes, and relevant listed patents where applicable. Entecavir tablets and oral solution are subject to generic competition in the United States, and multiple abbreviated new drug applications have been approved for entecavir products (FDA, 2024).

A commercial diligence review should separate:

• Historical Baraclude patents.
• Current Orange Book-listed patents.
• Patents covering the active ingredient.
• Patents covering dosage forms or methods of use.
• Unlisted process, packaging, trade-secret, and know-how rights.
• State-specific substitution status for each approved generic.

Orange Book status is not a complete measure of freedom to operate. A generic product can face litigation involving patents that are not listed in the Orange Book, although such patents do not automatically create the same ANDA approval delay as a properly listed patent.

When did entecavir lose exclusivity and when can generics launch?

Baraclude's principal compound protection ended years after the 2005 approval, subject to patent-term calculations and pediatric exclusivity. U.S. generic entecavir products entered after patent and regulatory barriers were resolved. Current generic competition means that the commercial opportunity is no longer based on first-to-market compound exclusivity.

The relevant launch scenarios are:

Scenario	Commercial effect
Conventional 0.5 mg and 1 mg tablets	High price pressure and rapid substitution
Generic oral solution	Smaller market with higher formulation and packaging value
Pediatric mini-tablet or dispersible product	Potential differentiation and less direct competition
Authorized generic or licensed product	Lower development risk but reduced margin
Complex formulation	Greater regulatory burden but possible niche protection
Non-U.S. launch	Timing depends on local patent, registration, and reimbursement rules

Paragraph IV challenges were relevant during the original generic-entry period. Today, the more important question for a new entrant is whether a proposed product relies on a new formulation, a new indication, or a different regulatory pathway. A conventional ANDA must establish pharmaceutical equivalence and bioequivalence to the relevant reference product. A materially different dosage form may require additional clinical or pharmacokinetic evidence.

What formulation patents could be commercially valuable?

Formulation patents have the strongest value when they solve an identifiable problem and produce measurable performance. Candidates include:

Taste-masked pediatric compositions

Claims may cover a combination of entecavir with a coating polymer, ion-exchange resin, lipid carrier, or multiparticulate system. The commercial value depends on demonstrated taste improvement, acceptable release, and pediatric usability.

Stable oral solutions

A useful patent could cover a defined pH range, preservative system, sweetener combination, container-closure system, or stability profile. Broad claims to common sweeteners or buffers are likely to face validity and obviousness challenges.

Orally disintegrating tablets

Patentable features could include a specific low-dose blend, rapid disintegration time, taste masking, friability control, and bioequivalent drug release.

Modified-release or long-acting systems

These are technically more ambitious. Entecavir is currently marketed as an immediate-release oral product. A sustained-release or implantable product would require substantial pharmacokinetic and clinical validation, and its commercial rationale would depend on adherence benefits.

Manufacturing process patents

Low-dose blending, granulation, compression, coating, and impurity-control processes may create practical barriers even when compound patents have expired. Process patents are most valuable when they provide a reproducible quality advantage that is difficult to design around.

Which companies are challenging or competing with Baraclude?

Entecavir is a genericized small-molecule market rather than a biosimilar market. Generic competition has come from companies including Teva, Mylan/Viatris, Aurobindo, Dr. Reddy's Laboratories, Cipla, Zydus, Sun Pharma, and regional manufacturers, depending on jurisdiction and product presentation. Approval and marketing status vary by country and time.

The competitive landscape divides into four groups:

1. Large generic companies with low-cost tablet manufacturing.
2. Regional suppliers focused on tender and reimbursement markets.
3. Specialty companies supplying oral liquids and pediatric products.
4. Contract manufacturers offering private-label entecavir products.

Biosimilar risk is not applicable because entecavir is a chemically synthesized small molecule. The relevant competitive risks are ANDA entry, price erosion, therapeutic substitution, tender competition, and alternative HBV therapies such as tenofovir disoproxil fumarate and tenofovir alafenamide.

How does entecavir compare with tenofovir for commercial formulation strategy?

Factor	Entecavir	Tenofovir products
Main dosage form	Low-dose oral tablet; oral solution available	Primarily oral tablets
Dose-load challenge	High, because dose is 0.5-1 mg	Lower sensitivity in many tablet designs
Pediatric liquid opportunity	Established reference solution	Product and market dependent
Resistance positioning	Important in treatment selection	Strong clinical and commercial competition
Excipient differentiation	Taste masking, mini-tablets, solution stability	Tablet size, fixed-dose combinations, tolerability
Biosimilar pathway	Not applicable	Not applicable for small-molecule products
Generic price pressure	High	High

Entecavir's low dose creates more formulation opportunity per milligram of active ingredient, but the total market is constrained by generic competition and the availability of tenofovir-based regimens.

What manufacturing and intellectual-property barriers affect entecavir?

The main barriers are operational rather than compound-patent based:

• Achieving uniform distribution of a submilligram-to-low-milligram dose.
• Maintaining blend uniformity across commercial batch sizes.
• Controlling dissolution after lubricant addition.
• Protecting oral solution stability during shelf life and in-use storage.
• Demonstrating preservative effectiveness.
• Validating dose delivery through oral syringes.
• Managing excipient variability across suppliers.
• Establishing impurity and degradation-product controls.
• Meeting global nitrosamine, elemental impurity, and extractables requirements where applicable.
• Securing reliable API supply at competitive cost.

For tablets, continuous manufacturing or tightly controlled dry blending may reduce scale-up risk. For liquids, container-closure compatibility and microbiological robustness can be more important than the active ingredient cost.

What revenue exposure and commercial opportunities exist?

The largest revenue opportunity is unlikely to come from another conventional tablet. That segment is exposed to immediate price erosion and tender substitution. Higher-value opportunities include:

Opportunity	Market attractiveness	Main risk
Standard generic tablets	Volume-driven	Severe price competition
Generic oral solution	Moderate	Smaller market and stability burden
Pediatric mini-tablets	Potentially high	Taste and bioequivalence complexity
Orally disintegrating tablets	Moderate	Need to demonstrate patient benefit
Preservative-free unit doses	Niche	Packaging cost and stability validation
Authorized generic licensing	Moderate	Lower margin and dependence on partner
Emerging-market liquids	Moderate	Registration and reimbursement variability
Combination products	Potentially high	Clinical, patent, and regulatory complexity

Revenue exposure for the original innovator has declined with generic entry. The remaining branded value is linked to physician familiarity, supply continuity, pediatric use, and markets where generic penetration is incomplete. For a new entrant, margin preservation depends on presentation differentiation rather than active-ingredient exclusivity.

What regulatory strategy applies to a new entecavir product?

A conventional tablet that matches the reference product is generally suited to an ANDA pathway in the United States. A substantially different formulation may require a different regulatory strategy, depending on the claims, dosage form, and clinical evidence.

The regulatory priorities are:

• Pharmaceutical equivalence to the reference product.
• Bioequivalence at the relevant strength or strengths.
• Demonstration of dissolution similarity.
• Content uniformity suitable for the low-dose product.
• Excipient safety and compatibility.
• Stability under ICH conditions.
• Microbial control for oral liquids.
• Accurate dosing-device performance.
• Pediatric acceptability data when positioning a pediatric product.

A new liquid, mini-tablet, or orally disintegrating product should be evaluated for whether it can rely on an existing reference product or requires a more complex bridging strategy. Excipient changes that alter absorption, gastrointestinal transit, or dissolution can increase development risk even when the active ingredient is unchanged.

Key Takeaways

• Entecavir is a genericized small-molecule HBV drug with no biosimilar pathway.
• The principal commercial opportunity is not compound exclusivity but dosage-form differentiation.
• Low-dose content uniformity is the central tablet-development challenge.
• Lactose, microcrystalline cellulose, crospovidone, povidone, and conventional film-coating systems provide a practical generic platform.
• Oral solution development offers opportunities in taste, preservative strategy, dosing accuracy, and packaging.
• Pediatric mini-tablets and orally disintegrating tablets have greater differentiation potential than another standard tablet.
• Formulation patents need defined composition and performance claims; common excipient combinations alone are unlikely to provide durable protection.
• Generic tablets face severe price competition, while liquids and pediatric formats can support better margins.
• Manufacturing know-how, process control, API quality, and container-closure performance may be more important than expired compound patents.
• The U.S. regulatory route for a conventional product is generally an ANDA, subject to product-specific FDA requirements.

FAQs

Is entecavir a biologic that can face biosimilar competition?

No. Entecavir is a chemically synthesized small molecule. Competition occurs through generic drug applications, not biosimilar applications.

Which excipient is best for improving entecavir tablet content uniformity?

No single excipient determines uniformity. A controlled lactose-microcrystalline cellulose diluent system, suitable particle-size distribution, ordered blending, and validated low-shear transfer process are more important than any individual excipient.

Can entecavir be formulated as a sugar-free pediatric liquid?

Yes. A sugar-free formulation can use polyols and high-intensity sweeteners, but developers must control viscosity, osmolality, taste, preservative efficacy, pH, and stability.

Are entecavir formulation patents still commercially important?

They can be important for differentiated liquids, orally disintegrating tablets, pediatric systems, and manufacturing processes. The original compound patent is no longer the primary commercial barrier in the United States.

What is the highest-value excipient opportunity for entecavir?

A pediatric formulation combining taste masking, accurate low-volume dosing, stable packaging, and convenient administration has the strongest potential for differentiation relative to conventional generic tablets.

References

1. DailyMed. (2024). Baraclude: Entecavir tablet and oral solution prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2023a). Baraclude (entecavir) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Patent No. 5,206,244. (1993). Carbocyclic nucleosides and pharmaceutical compositions. United States Patent and Trademark Office.

5. U.S. Food and Drug Administration. (2005). FDA approves Baraclude for chronic hepatitis B. FDA.

6. World Health Organization. (2024). WHO guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. WHO.